Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0121 | 0.793 | 0.7841 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0148 | 1 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0074 | 0.427 | 0.4024 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0229 | 0.0229 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.1777 | 0.171 |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.394 | 0.389 |
Schistosoma mansoni | bromodomain containing protein | 0.0063 | 0.3367 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.3091 | 0.3091 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0229 | 0.0679 |
Loa Loa (eye worm) | hypothetical protein | 0.0121 | 0.793 | 0.7913 |
Loa Loa (eye worm) | hypothetical protein | 0.0121 | 0.793 | 0.7913 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.3091 | 0.3091 |
Onchocerca volvulus | Huntingtin homolog | 0.0121 | 0.793 | 0.5 |
Echinococcus multilocularis | muscleblind protein | 0.0148 | 1 | 1 |
Onchocerca volvulus | Huntingtin homolog | 0.0121 | 0.793 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 1 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0036 | 0.126 | 0.126 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 1 | 1 |
Echinococcus granulosus | muscleblind protein | 0.0148 | 1 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.1442 | 0.1076 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.1448 | 0.1378 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0229 | 0.0229 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0036 | 0.126 | 0.126 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.163 | 0.1562 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0081 | 0.0242 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.